Medicine used for treating recurrent pulmonary tuberculosis

Abstract

The invention provides a medicine used for treating recurrent pulmonary tuberculosis. The medicine comprises, by weight, 5-12 parts of moxifloxacin, 18-24 parts of p-aminobenzoic isoniazid salicylate, 5-12 parts of rifabutin, 36-45 parts of pyrazinamide, and 18-24 parts of ethambutol. As a result of clinical verification, with the recurrent pulmonary tuberculosis medicine provided by the invention, recurrent pulmonary tuberculosis treatment period can be shortened, and a cure rate can be greatly improved.

Description

technical field [0001] The invention relates to a medicine for medical use, in particular to a medicine for treating recurrent pulmonary tuberculosis. Background technique [0002] For 90% of newly diagnosed pulmonary tuberculosis patients, tuberculosis can be cured through standard newly diagnosed pulmonary tuberculosis chemotherapy regimen and strict chemotherapy management (DOTS strategy). However, for patients with relapsed pulmonary tuberculosis, the treatment effect is unsatisfactory due to the complex situation of recursed pulmonary tuberculosis. Retreated pulmonary tuberculosis patients have become the mainstay of drug-resistant tuberculosis in my country, especially multidrug-resistant tuberculosis (PDR-TB), multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). major groups. Therefore, paying attention to the research and development of chemotherapy regimens for retreatment of pulmonary tuberculosis will help to control the...

AI Technical Summary

Problems solved by technology

[0005] There are following defects in the commonly used retreatment pulmonary tuberculosis standard chemotherapeutic regimen now: firstly, the treatment time is generally 8 months, and the course of treatment is longer

According to the report of Wan Liya et al., the cure rate of initial treatment failure cases after regular treatment is only 53.6%, and the curative effect is significantly reduced.